650 Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – interim results from the GOBLET study

Abstract

BackgroundPelareorep (pela) is an intravenously administered, non-genetically modified oncolytic reovirus that selectively kills tumor cells and activates both innate and adaptive immune responses. In prior clinical trials, pela was shown...